BioForum - Bispecific Antibodies / AXC:
Development, Manufacturing and Regulatory Pathways

About the event

The BioForum “Bispecific Antibodies / AXC: Development, Manufacturing and Regulatory Pathways”, delivered by BioMelbourne Network in collaboration with ProBio, will explore the development, manufacturing and regulatory pathways shaping the next wave of antibody-based therapeutics.

With a focus on bispecific antibodies and selected antibody-X conjugate (AXC) modalities, including radiopharmaceutical drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs), the forum will examine both the promise of these approaches and the distinct challenges they present from preclinical through to clinical and commercial translation.

Bringing together international and local speakers, this hybrid BioForum will share practical insights into the challenges and opportunities of next-generation biologics. Delegates attending in person or online will gain valuable perspectives on design, manufacturability, scalability and regulatory strategy, and on how organisations are reducing development risk and advancing promising therapies towards approval.

Who should attend?

This event is particularly relevant for:

• Biotech and biopharma leaders in antibody therapeutics
• Discovery and translational scientists advancing next-generation modalities
• CMC, manufacturing and scale-up specialists in complex biologics
• Regulatory, clinical and quality professionals navigating approval pathways
• Investors, IP advisers and legal specialists supporting translation and commercial readiness
• Specialist partners in manufacturing, scale-up and technical development support

Event details

Date: Thursday 28 May 2026

Time: 4:00 pm - 6:30 pm AEST

Venue: Davies Collison Cave, Level 1, 500 Bourke St, Melbourne 3000

Format: In person and online.

Ticket pricing: Tickets are complimentary but registration is essential.

Host: Vicky Jones, Acting CEO, BioMelbourne Network